Starting from a deep knowledge of the disease, we have built a technological platform able to “read” the signal of cancer in blood.
We began with extensive tissue, buffy coat and plasma WGBS profiling to discover the most informative markers for individual cancer types.
Our multi-omics approach combines Methylomics and Fragmentomics to analyze multiple layers of cancer signal and identify pre-cancer and early-stage cancers with high accuracy.
Our tools facilitate extraordinarily accurate marker discovery with the most informative DNA regions.
We combine our proprietary algorithms – AMBER™, which scores cancer signal using read-wise Methylation patterns and CODEdX™, which looks at open chromatin region based for Fragmentation patterns – with machine learning to achieve the highest accuracy in early cancer detection.
A targeted Next Generation Sequencing (NGS) platform reads hundreds of marker regions with high accuracy and fits seamlessly into any clinical lab at economic cost.
We are collaborating with leading hospitals, integrated health systems, medical centers and biobanks around the world to conduct studies in order to further develop and validate UDX's blood test for early cancer detection.
+100
CLINICAL INSTITUTIONS
6
Countries
+12k
subjects
3
trials
We are currently conducting the USOPTIVAL Study, a prospective multi-center observational study of more than 1,200 eligible subjects from the U.S. to evaluate the performance of UDX's cfDNA marker panel for CRC and advanced adenoma detection. More information in ClinicalTrials.gov
